Loading
A phase 1 trial of Sovilnesib run by Volastra Therapeutics, Inc., now recruiting.
A Study of Sovilnesib in Subjects With Ovarian Cancer is a phase 1 interventional study registered as NCT06084416 by Volastra Therapeutics, Inc., with 150 participants planned, started 2024-04-04, primary completion expected 2027-11. Conditions recorded: High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability. Interventions recorded: Sovilnesib.
Shares Sovilnesib, Volastra Therapeutics and the tag pipeline.
Shares Volastra Therapeutics, High-grade serous ovarian cancer and the tag pipeline.
Shares High-grade serous ovarian cancer and the tag pipeline.
Shares Volastra Therapeutics and the tag pipeline.
Shares High-grade serous ovarian cancer and the tag pipeline.
Shares High-grade serous ovarian cancer and the tag pipeline.
Shares High-grade serous ovarian cancer and the tag pipeline.
Shares High-grade serous ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/